New Shared Synthetic Replikin Cancer Vaccines Conserved Genomic Replikin Peptides were found to be Shared in Histologically Different Common Lethal Human Cancers

BOSTON, Jan. 22, 2013 /PRNewswire/ -- Replikins Ltd. and Brain Research Associates announced today that specific conserved genomic Replikin peptide sequences for the first time have been found to be shared among different histological cancer types, permitting the seven day synthesis of new shared cancer vaccines.

(Photo: )

Each of the shared Replikins was found to be present in multiple malignancies. The genomic Replikin®Count (number of Replikin genomic structures per 100 amino acids) relates quantitatively to the five year human mortality rate for each cancer type, the first genomic structures found to be so related (1) (see Figure). The lowest genomic Replikin®Counts were found in those cancers which have the lowest five year mortality rates, as in prostate and thyroid cancer; and the highest Replikin®Counts were found in glioblastoma multiforme, pancreatic and lung cancer, which have the highest mortality rates.

Genomic Replikins in cancer are quantitatively predictive of mortality rate, as recently also found by Replikins Ltd. in viral infectious disease (1-10), and these Replikin structures enable the production of effective specific synthetic vaccines in seven days (9,10). These genomic Replikins in cancer are also the basis of aids for cancer diagnosis, as the Antimalignin Antibody in Serum (AMAS)®Test, the anti-Replikin antibody test, which was shown to be elevated in all common cancers (1). This test has proved useful in helping to distinguish benign from malignant growths, when the cancer is small and barely detected by radiographic techniques, eg. as an aid in diagnosing cancer early in lung and in breast lesions (1). The AMAS®Test can now also be used as a marker to track cancer prevention by synthetic Replikins vaccines (9,10) in high risk subjects, and to track efficacy of treatment by synthetic Replikins blockers (10). 

Anne Borsanyi


1. Bogoch S and Bogoch ES. Genome Replikin CountTM  Predicts Increased Lethality of Cancer. Nature Precedings doi:10.1038/npre.2012.7143.1

2. Bogoch, S. and Bogoch, E.S. Genome Replikin CountTM Predicts Increased Infectivity/Lethality of Viruses. Nature Precedings npre2012.7144. 04April 2012. 

3. Bogoch, S. and Bogoch, E.S. Prediction of specific virus outbreaks made from the increased concentration of a new class of virus genomic peptides, replikins. Nature Precedings doi:10.1038/npre.2011.6279.1.23Aug 2011. 

4. Bogoch,S. and Bogoch, ES. Bogoch Replikins Pandemic Prevention: Increase of Strain-Specific Influenza Genomic Replikin Counts, Having Predicted Outbreaks and their Location Seven Times Consecutively, Up to Two Years in Advance, Provides Time for Prevention of Pandemics. Nature Precedings.doi:10.1038/npre.2012.6952.1 01 March, 2012

5. Bogoch, S. and Bogoch, E.S. Marked Rise in Replikin Counts in H5N1 Influenza Virus Localized to Lethality Gene pB1.Nature Precedings doi:10.1038/npre.2011.6420.1

6. Bogoch S, Bogoch ES.   Replikins Pandemic Prevention: Increase of Strain-Specific Influenza Genomic Replikin Counts, Having Predicted Outbreaks and their Location Seven Times Consecutively, Up to Two Years in Advance, Provides Time for Prevention of PandemicsNature Precedings doi:10.1038/npre.2012.6952.1                                                                       

7. Report #49. Replikins Press<>.Discovered Evolution of Genomic Sequences -- from Ocean Archaea to Brain Cancer -- Leads to New Synthetic Replikin Vaccines for Infectious Diseases and Cancer, June 19, 2012

8. Report #42,  Replikins Press<>. UN Food and Agriculture Organization (FAO) discussion of Replikins, DVM Newsmagazine, (Sept. 8, 2011).

9. Jackwood, MW et al. Efficacy of a Replikin Peptide Vaccine against Low Pathogenicity Avian Influenza H5 Virus. Avian Diseases 53(4): 613‐617, 2009

10. Report # 17. Replikins Press<>.Replikins Oral Vaccine Synthesized in 7 days protects 91% of Shrimp Against Lethal Virus . March 11, 2008.

This press release was issued through eReleases® Press Release Distribution. For more information, visit

SOURCE Replikins


More by this Source

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.


PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.